Previous 10 | Next 10 |
Prothena Corporation (PRTA) Q4 2020 Earnings Conference Call February 11, 2021 08:30 ET Company Participants Ellen Rose - Head of Communications Gene Kinney - President, Chief Executive Officer & Director Tran Nguyen - Chief Financial Officer & Chief Operating Officer Wagner Zago - Ch...
Prothena (PRTA): Q4 GAAP EPS of -$0.77 in-line.Revenue of $0.36M (+38.5% Y/Y) beats by $0.18M.Shares -1.5% PM.Press Release For further details see: Prothena EPS in-line, beats on revenue
Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million provides funding to advance the R&D pipeline Announced confirmatory Phase...
DUBLIN, Ireland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it...
Gainers: Cassava Sciences (SAVA) +126%.Ocugen (OCGN) +75%.American Resources (AREC) +51%.Lizhi (LIZI) +46%.Aeterna Zentaris (AEZS) +35%.Moleculin Biotech (MBRX) +35%.Holicity (HOL) +35%.Prothena (PRTA) +32%.TETRA Technologies (TTI) +32%.Artelo Biosciences (ARTL) +29%.Losers: Ga...
Prothena Corp. (PRTA) shares surged in premarket trading after BTIG analyst Robert Hazlett upgraded shares to buy.His price target is $29.Hazlett says a registration-enabling study, AFFIRM-AL, for birtamimab, its monoclonal antibody candidate for Mayo Stage IV AL amyloidosis patients, can hap...
Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...
Gainers: [[PRTA]] +35.6%. [[CRBP]] +30.0%. [[GPRO]] +6.8%. [[VYNE]] +5.7%. [[LOTZ]] +3.6%.Losers: [[CRUS]] -7.5%. [[RMBS]] -6.3%. [[STRO]] -6.0%. [[ALTR]] -5.4%. [[NERV]] -5.1%. For further details see: PRTA, RMBS, NERV and GPRO among after-hours movers
Prothena (PRTA) announces that it will go ahead with a confirmatory Phase 3 AFFIRM-AL study for its AL amyloidosis treatment birtamimab following multiple discussions with the U.S. FDA, with the aim of initiating the the trial by mid-2021.AL amyloidosis is a rare inherited diso...
Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months) SPA agreement with FDA to enable registration of birtamimab at unprecedented p &l...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...